{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:enekinragene inzadenovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:cretostimogene grenadenorepvec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:opilrelagene atradenorepvec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:encoberminogene rezmadenovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:alferminogene tadenovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03921021: Phase 2 Interventional Completed Esophagogastric Adenocarcinoma
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01436968: Phase 3 Interventional Active, not recruiting Prostate Cancer
(2011)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03398655: Phase 3 Interventional Completed Recurrent Platinum Resistant Ovarian Cancer
(2017)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03780049: Phase 3 Interventional Unknown status Hepatocellular Carcinoma
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03563144: Phase 2 Interventional Withdrawn Metastatic Pancreatic Cancer
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE